Opsismodysplasia

Opsismodysplasia is a rare genetic disorder that affects the development of the skeleton. The condition is characterized by short stature and skeletal abnormalities such as short limbs and a small chest. The name "opsismodysplasia" comes from the Greek words "opsis" (appearance), "mo" (late), and "dysplasia" (abnormal growth or development).

Signs and Symptoms

Individuals with opsismodysplasia typically have a short stature, with a height that is significantly below average for their age and sex. They may also have a small chest and short limbs. Other skeletal abnormalities can include a large head (macrocephaly), a prominent forehead, and a flat face with a small nose and mouth. Some individuals may also have abnormalities of the hands and feet, such as short fingers and toes.

Causes

Opsismodysplasia is caused by mutations in the INO80E gene. This gene provides instructions for making a protein that is involved in the regulation of DNA repair and the control of gene activity. Mutations in the INO80E gene disrupt the normal function of the protein, leading to the skeletal abnormalities seen in opsismodysplasia.

Diagnosis

The diagnosis of opsismodysplasia is typically based on the presence of characteristic signs and symptoms. Genetic testing can confirm the diagnosis by identifying a mutation in the INO80E gene.

Treatment

There is currently no cure for opsismodysplasia. Treatment is focused on managing the symptoms and improving the quality of life for individuals with the condition. This can include physical therapy to improve mobility and surgical interventions to address skeletal abnormalities.

Prognosis

The prognosis for individuals with opsismodysplasia varies. Some individuals have a normal lifespan, while others may have life-threatening complications in infancy or early childhood.

See Also

• Genetic disorder
• Skeletal dysplasia
• Short stature
• INO80E

Opsismodysplasia Resources
Need Help Finding a Doctor? WikiMD's DocFinder can help find general and specialist physicians.	Latest articles Most recent articles Ongoing trials.